SCHEMBL4274141

SCHEMBL4274141

COc1ccc(Cl)cc1Nc1ncnc(Cl)c1C#N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 2/20 0.47
LMNA P02545 2/20 0.47
FLT1 P17948 2/20 0.46
KDR P35968 2/20 0.46
FGFR1 P11362 1/20 0.46
EPHB2 P29323 1/20 0.46
FLT4 P35916 1/20 0.46
CHEK1 O14757 1/20 0.45
HPGD P15428 2/20 0.44
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 3/20 0.42
HTT P42858 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
EGFR P00533 2/20 0.41
ERBB2 P04626 1/20 0.41
RAF1 P04049 1/20 0.41
BRAF P15056 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4268667 0.82 SRC (0.58) SRCKDREGFRERBB2
SCHEMBL4266699 0.81 SRC (0.48) SRCTSHRMAPK1KDM4EEGFR
SCHEMBL4276211 0.81 EGFR (0.55) LMNAKDRFLT4GAATSHR
SCHEMBL4266486 0.79 SRC (0.57) SRCKDRHTT
SCHEMBL4266307 0.78 EGFR (0.53) SRCKMT2AHTTEGFRMEN1
SCHEMBL4270705 0.77 CLK1 (0.47) SRCFLT1KDRFGFR1EPHB2
SCHEMBL4267681 0.77 EGFR (0.48) FLT1KDRFLT4TSHRKMT2A
SCHEMBL23565733 0.73 KMT2A (0.61) LMNAHPGDTSHRMAPK1KMT2A
SCHEMBL4267388 0.72 TSHR (0.53) SRCHPGDTSHRMAPK1KDM4E
SCHEMBL4260873 0.72 MAPK13 (0.46) LMNAKDRTSHRMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579356-B2 Thia-tetraazaacenaphthylene kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2009-08-25 US disclosed
US-20070265264-A1 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-15 US disclosed
WO-2006118749-A1 THIA-TETRAAZAACENAPHTHYLENE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265264-A1 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide ADK, MAP3K9, MAP4K5 SRC 339/4885LMNA 3244/4885FLT1 1773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.